HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Acute and chronic alcohol exposure impair the phagocytosis of apoptotic cells and enhance the pulmonary inflammatory response.

AbstractBACKGROUND:
Alcohol abuse increases the risk for acute respiratory distress syndrome (ARDS). Efferocytosis, the clearance of apoptotic cells, is important in the resolution of inflammation and is regulated by RhoA and rho kinase (ROCK) activation. The effects of alcohol on pulmonary Rho pathway activation and efferocytosis have not been determined. We hypothesize that acute and chronic alcohol exposure impair pulmonary efferocytosis, leading to heightened inflammation during ARDS.
METHODS:
For in vivo experiments, C57BL/6 mice received either a single intraperitoneal injection of alcohol or chronic ethanol-in-water for 8 weeks prior to intratracheal instillation of apoptotic cells or lipopolysaccharide (LPS). Bronchoalveolar lavage (BAL) was performed for cells counts, calculation of the phagocytic index (PI), and Rho activity measurements. For in vitro studies, primary alveolar macrophages were cultured in alcohol (25-100 mM) and then co-cultured with apoptotic cells. RhoA activity was determined following alcohol exposure, and the PI was determined before and after treatment with the ROCK inhibitor, Y27632.
RESULTS:
Acute alcohol exposure was associated with impaired efferocytosis. Following LPS exposure, acute alcohol exposure was also associated with increased BAL neutrophils. Chronic alcohol exposure alone did not alter efferocytosis. However, following exposure to LPS, chronic alcohol exposure was associated with both impaired efferocytosis and increased BAL neutrophils. In vitro alcohol exposure caused a dose-dependent decrease in efferocytosis. Despite the fact that RhoA activity was decreased by alcohol exposure and RhoA inhibition did not alter the effects of alcohol on efferocytosis, treatment with the Rho kinase inhibitor, Y27632, reversed the effects of alcohol on efferocytosis.
CONCLUSIONS:
Acute alcohol exposure impairs pulmonary efferocytosis, whereas exposure to chronic alcohol is only associated with impaired efferocytosis following LPS-induced lung injury. Both forms of alcohol exposure are associated with increased alveolar neutrophil numbers in response to LPS. The acute effects of alcohol on efferocytosis appear to be mediated, at least in part, by RhoA-independent activation of ROCK. Further studies are needed to dissect the differences between the effects of acute and chronic alcohol exposure on efferocytosis and to determine the effects of alcohol on alternative activators of ROCK.
AuthorsDarren M Boé, Tiffany R Richens, Sarah A Horstmann, Ellen L Burnham, William J Janssen, Peter M Henson, Marc Moss, R William Vandivier
JournalAlcoholism, clinical and experimental research (Alcohol Clin Exp Res) Vol. 34 Issue 10 Pg. 1723-32 (Oct 2010) ISSN: 1530-0277 [Electronic] England
PMID20608904 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2010 by the Research Society on Alcoholism.
Chemical References
  • Amides
  • Lipopolysaccharides
  • Pyridines
  • Y 27632
  • Ethanol
  • rho-Associated Kinases
  • RhoA protein, mouse
  • rho GTP-Binding Proteins
  • rhoA GTP-Binding Protein
Topics
  • Amides (pharmacology)
  • Animals
  • Apoptosis (physiology)
  • Bronchoalveolar Lavage Fluid (chemistry, cytology)
  • Cells, Cultured
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Ethanol (administration & dosage, adverse effects)
  • Female
  • Lipopolysaccharides
  • Macrophages, Alveolar (metabolism)
  • Mice
  • Mice, Inbred C57BL
  • Phagocytosis (drug effects, physiology)
  • Pneumonia (chemically induced, physiopathology)
  • Pyridines (pharmacology)
  • Respiratory Distress Syndrome (chemically induced, metabolism, physiopathology)
  • rho GTP-Binding Proteins (analysis)
  • rho-Associated Kinases (antagonists & inhibitors)
  • rhoA GTP-Binding Protein

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: